Pharmaceutical and Healthcare Industry in Russia - Forecast and Analysis 2021

Pharmaceutical and Healthcare Industry in Russia - Forecast and Analysis 2021

The Russian healthcare system is primarily funded by the federal government, though the industry is making a significant shift towards private healthcare spending in recent years. The country has made considerable progress in managing the COVID-19 pandemic and even released the first-ever vaccine to protect its population against the novel coronavirus infection. However, the number of new infections and deaths from COVID-19 still continues. The country is hoping for a rapid vaccination program for its adult population.

There is no denying that the Russian pharmaceutical sector is one of the biggest in the CEE market and globally as well. The Russian economy has been facing a period of recession in recent years. The COVID-19 situation is also expected to negatively impact the healthcare and pharmaceutical sectors further. At the same time, there remains a vast difference between the rich and poor population and their access to healthcare.

While several domestic players are active in the industry, the pharmaceutical industry in Russia is primarily dominated by foreign companies like Sanofi, Johnson & Johnson, AstraZeneca, and many others. Local companies that are active in the sector include Veropharm, Pharmstandard, and Pharmsynthez.

Aruvian Research presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of Russia in its research report Pharmaceutical and Healthcare Industry in Russia – Forecast and Analysis 2021. The report covers the following data:

• An in-depth coverage of the pharmaceutical and healthcare industry in Russia by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
• We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for medical research and clinical trials in Russia.
• A SWOT analysis of the Russian pharmaceutical and healthcare industry.
• A Porter's Five Forces Strategic Analysis of the Russian pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.
• We take an up-close view of the regulatory framework governing the Russian pharmaceutical and healthcare industry, and the challenges being faced in terms of intellectual property rights.
• Competition in the industry, along with an in-depth analysis of the both the domestic and multinational players in the sector like Pharmstandard OJSC, Veropharm, AstraZeneca, Johnson & Johnson, Novartis, and many others are included.

A detailed forecast of the Russian pharmaceutical and healthcare industry by segments completes this comprehensive analysis.